We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Integra's (IART) SIA Buyout Widens Breast Reconstruction Scope
Read MoreHide Full Article
Integra LifeSciences (IART - Free Report) recently acquired Surgical Innovation Associates (SIA), the developer and marketer of the resorbable synthetic matrix for plastic and reconstructive surgery, called DuraSorb. Financial terms of the deal were kept under wraps.
Integra expects this acquisition to be aligned with the company’s global expansion strategy in breast reconstruction. This strategy includes expansion plans to access the U.S. market with FDA-approved devices for use in implant-based breast reconstruction (IBBR) procedures. This will help Integra to position itself as a prominent global player in the field of IBBR procedures.
More on the News
Post the acquisition, SIA’s DuraSorb’s resorbable synthetic technology is expected to strengthen Integra’s plastic and reconstructive surgery portfolio. This portfolio already includes SurgiMend PRS, a xenograft surgical matrix. With SurgiMend PRS, Integra is the first and the only manufacturer to date to submit a pre-market approval (PMA) application for a surgical matrix for use as soft tissue support in IBBR. This PMA is currently under review with the FDA.
On the other hand, SIA is conducting an investigational device exemption study in the United States evaluating the safety and effectiveness of DuraSorb with a target to get a PMA in IBBR.
Huge Market Prospect
The breast reconstruction market currently represents an attractive growth opportunity globally on rising incidents of breast cancer, growing awareness and reimbursement availability. Going by the markets and markets data, this market is projected to reach $647 million by 2026, at a CAGR of 2.7%.
With its investment in SIA, Integra’s surgical reconstruction business is expected to get bolstered by this huge growth opportunity in the breast reconstruction space. According to the company, by offering two distinct product solutions, SurgiMend and DuraSorb, to plastic and reconstructive surgeons, it aims at addressing various clinical, contracting, and economic needs across different care sites.
Integra's Other Developments in Terms of Portfolio Expansion
Earlier this year, Integra launched two new products. First, the Aurora Evacuator with Coagulation capability in the United States that safely addresses and evacuates blood in the brain caused by hemorrhagic stroke. Second, it launched the Neutus EVD system, the company’s first external ventricular drain in China.
In Tissue Technologies, the company’s NeuraGen 3D products targeted for mid-gap peripheral nerve repair should boost sales momentum.
Zacks Rank and Key Picks
Currently, Integra carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are ShockWave Medical, Inc. (SWAV - Free Report) , Orthofix Medical Inc. (OFIX - Free Report) and Merit Medical System (MMSI - Free Report) .
ShockWave Medical, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 33.1% for 2023. The company’s earnings surpassed estimates in all the trailing four quarters, the average beat being 180.1%.
Merit Medical, currently carrying a Zacks Rank of 2, reported third-quarter 2022 adjusted EPS of 64 cents, which beat the Zacks Consensus Estimate by 20.8%. Revenues of $287.2 million outpaced the consensus mark by 5.2%.
Merit Medical has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average being 25.4%.
Orthofix Medical currently carrying a Zacks Rank of 1, reported third-quarter 2022 adjusted EPS of 13 cents, which beat the Zacks Consensus Estimate by a stupendous 550%. Revenues of $114 million outpaced the consensus mark by 2.7%.
Orthofix Medical has an estimated next-year growth rate of 58.97%. OFIX’s earnings surpassed estimates in the trailing three quarters and missed in one, the average being 129.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Integra's (IART) SIA Buyout Widens Breast Reconstruction Scope
Integra LifeSciences (IART - Free Report) recently acquired Surgical Innovation Associates (SIA), the developer and marketer of the resorbable synthetic matrix for plastic and reconstructive surgery, called DuraSorb. Financial terms of the deal were kept under wraps.
Integra expects this acquisition to be aligned with the company’s global expansion strategy in breast reconstruction. This strategy includes expansion plans to access the U.S. market with FDA-approved devices for use in implant-based breast reconstruction (IBBR) procedures. This will help Integra to position itself as a prominent global player in the field of IBBR procedures.
More on the News
Post the acquisition, SIA’s DuraSorb’s resorbable synthetic technology is expected to strengthen Integra’s plastic and reconstructive surgery portfolio. This portfolio already includes SurgiMend PRS, a xenograft surgical matrix. With SurgiMend PRS, Integra is the first and the only manufacturer to date to submit a pre-market approval (PMA) application for a surgical matrix for use as soft tissue support in IBBR. This PMA is currently under review with the FDA.
Integra LifeSciences Holdings Corporation Price
Integra LifeSciences Holdings Corporation price | Integra LifeSciences Holdings Corporation Quote
On the other hand, SIA is conducting an investigational device exemption study in the United States evaluating the safety and effectiveness of DuraSorb with a target to get a PMA in IBBR.
Huge Market Prospect
The breast reconstruction market currently represents an attractive growth opportunity globally on rising incidents of breast cancer, growing awareness and reimbursement availability. Going by the markets and markets data, this market is projected to reach $647 million by 2026, at a CAGR of 2.7%.
With its investment in SIA, Integra’s surgical reconstruction business is expected to get bolstered by this huge growth opportunity in the breast reconstruction space. According to the company, by offering two distinct product solutions, SurgiMend and DuraSorb, to plastic and reconstructive surgeons, it aims at addressing various clinical, contracting, and economic needs across different care sites.
Integra's Other Developments in Terms of Portfolio Expansion
Earlier this year, Integra launched two new products. First, the Aurora Evacuator with Coagulation capability in the United States that safely addresses and evacuates blood in the brain caused by hemorrhagic stroke. Second, it launched the Neutus EVD system, the company’s first external ventricular drain in China.
In Tissue Technologies, the company’s NeuraGen 3D products targeted for mid-gap peripheral nerve repair should boost sales momentum.
Zacks Rank and Key Picks
Currently, Integra carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are ShockWave Medical, Inc. (SWAV - Free Report) , Orthofix Medical Inc. (OFIX - Free Report) and Merit Medical System (MMSI - Free Report) .
ShockWave Medical, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 33.1% for 2023. The company’s earnings surpassed estimates in all the trailing four quarters, the average beat being 180.1%.
ShockWave Medical has outperformed its industry in the past year. SWAV has gained 35% against the industry’s 32.6% fall in the past year. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Merit Medical, currently carrying a Zacks Rank of 2, reported third-quarter 2022 adjusted EPS of 64 cents, which beat the Zacks Consensus Estimate by 20.8%. Revenues of $287.2 million outpaced the consensus mark by 5.2%.
Merit Medical has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average being 25.4%.
Orthofix Medical currently carrying a Zacks Rank of 1, reported third-quarter 2022 adjusted EPS of 13 cents, which beat the Zacks Consensus Estimate by a stupendous 550%. Revenues of $114 million outpaced the consensus mark by 2.7%.
Orthofix Medical has an estimated next-year growth rate of 58.97%. OFIX’s earnings surpassed estimates in the trailing three quarters and missed in one, the average being 129.1%.